Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satellos Completes Phase 1 Enrollment for SAT-3247 in Healthy Volunteers
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Bloom Burton Securities
Deal Size : $40.0 million
Deal Type : Public Offering
Satellos Announces Pricing of US$40M Overnight Marketed Public Offering
Details : The Company intends to use the net proceeds from the Offering to advance clinical development of SAT-3247. It is being evaluated for the treatment of Duchenne Muscular Dystrophy.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Bloom Burton Securities
Deal Size : $40.0 million
Deal Type : Public Offering
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satellos Announces First Participant Dosed in Phase 1b Trial of SAT-3247 in DMD
Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satellos Demonstrates Improved Strength in DMD Canines with SAT-3247
Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...
Product Name : NM-1001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Details : Psilocybin has the capacity to influence cognition and behaviour as well as modulate the immune system and neural signaling pathways. Likewise, psilocybin is non-toxic and is not expected to have adverse side effects in humans.
Product Name : PLZ-1013
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As a new generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi syndrome (PWS), NASH, type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among oth...
Product Name : INV-202
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome, non-alcoholic steatohepatitis, type 1 diabetes, diabetic nephropathy and chronic kidney disea...
Product Name : INV-202
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INV-101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and non-alcoholic steatohepatitis (NASH).
Product Name : INV-101
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : INV-101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable